Immuneering Corp (IMRX) shareholders
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71+0.04 (+1.09%)
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
53.2%
34M of 65M shares
Institutional holders
112
38 new, 21 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
7 buys · 0 sales
Net bought $270.46K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (14.50%) | 8,787,052 | 14.50% | 13G (passive) | Sep 30, 2025 |
| Martin D. Hoe Joint filing with Empery Asset Management, LP (8.83%), Ryan M. Lane (8.83%) | 5,188,755 | 8.83% | 13G (passive) | Sep 30, 2025 |
| Benjamin J. Zeskind | 4,357,807 | 6.60% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 4,356,235 | 6.70% | 13G (passive) | Jun 30, 2026 |
| HBM Healthcare Investments (Cayman) Ltd. | 3,646,304 | 5.70% | 13G (passive) | Sep 26, 2025 |
| Merrin Investors LLC | 2,770,386 | 9.46% | 13G (passive) amendment | Mar 27, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,704,610 | 14.98% | $48.43M | +6,672 | 0.00% |
| BlackRock, Inc. | 4,374,020 | 6.75% | $21.83M | +2,866,762 | 0.00% |
| Sanofi | 2,708,559 | 4.18% | $13.52M | – | 2.53% |
| Vanguard Capital Management LLC | 2,286,434 | 3.53% | $11.41M | −1,907 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,936,076 | 2.99% | $9.66M | +106,888 | 0.00% |
| Geode Capital Management, LLC | 1,370,750 | 2.12% | $6.84M | +732,806 | 0.00% |
| State Street Corp | 1,001,995 | 1.55% | $5.00M | +733,475 | 0.00% |
| DCF Advisers, LLC | 790,000 | 1.22% | $3.94M | +648,538 | 0.70% |
| Marshall Wace, Llp | 731,897 | 1.13% | $3.65M | −1,264,688 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 601,255 | 0.93% | $3.00M | +200,892 | 0.01% |
| Alethea Capital Management, LLC | 472,935 | 0.73% | $2.36M | +450,000 | 0.98% |
| Summit Financial, LLC | 452,264 | 0.70% | $2.26M | +75,515 | 0.02% |
| UBS Group AG | 448,857 | 0.69% | $2.24M | +72,573 | 0.00% |
| Nuveen, LLC | 438,362 | 0.68% | $2.19M | New | 0.00% |
| Northern Trust Corp | 436,992 | 0.67% | $2.18M | +319,326 | 0.00% |
| Levin Capital Strategies, L.P. | 414,000 | 0.64% | $2.07M | +404,000 | 0.14% |
| Citadel Advisors LLC | 386,411 | 0.60% | $1.93M | −60,867 | 0.00% |
| Vanguard Fiduciary Trust Co | 360,764 | 0.56% | $1.80M | +38,726 | 0.00% |
| Vanguard Portfolio Management LLC | 359,085 | 0.55% | $1.79M | New | 0.00% |
| Gsa Capital Partners Llp | 343,303 | 0.53% | $1.71M | +266,551 | 0.11% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 112 | 34M | 53.2% | 38 / 35 | 21 / 21 | 9M | 4M |
| Q1 2026 | 95 | 29M | 45.3% | 30 / 27 | 22 / 18 | 8M | 7M |
| Q4 2025 | 86 | 32M | 49.0% | 31 / 27 | 12 / 13 | 10M | 5M |
| Q3 2025 | 68 | 26M | 40.2% | 33 / 24 | 6 / 4 | 23M | 0M |
| Q2 2025 | 39 | 4M | 5.9% | 11 / 8 | 6 / 7 | 1M | 1M |
| Q1 2025 | 35 | 4M | 6.9% | 5 / 9 | 9 / 12 | 1M | 1M |
| Q4 2024 | 42 | 4M | 6.6% | 7 / 12 | 10 / 3 | 0M | 0M |
| Q3 2024 | 38 | 4M | 6.7% | 7 / 8 | 17 / 27 | 1M | 6M |
| Q2 2024 | 59 | 10M | 14.8% | 28 / 10 | 19 / 19 | 4M | 6M |
| Q1 2024 | 51 | 12M | 18.5% | 7 / 15 | 23 / 8 | 1M | 5M |
| Q4 2023 | 52 | 16M | 25.0% | 4 / 18 | 17 / 4 | 0M | 1M |
| Q3 2023 | 52 | 17M | 26.2% | 7 / 24 | 11 / 4 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
73 funds held IMRX in Q2 2026, 36% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of IMRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 2,943,677 | 4.55% | $16.99M | 0.02% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 1,623,577 | 2.51% | $8.10M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,364,794 | 2.11% | $6.81M | 0.01% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,095,798 | 1.69% | $6.32M | 0.12% | May 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 906,762 | 1.40% | $4.52M | 0.03% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 828,054 | 1.28% | $4.78M | 0.02% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 719,805 | 1.11% | $4.15M | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 612,343 | 0.95% | $3.06M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 584,479 | 0.90% | $2.41M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 496,639 | 0.77% | $2.48M | 0.02% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 387,692 | 0.60% | $1.93M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 387,578 | 0.60% | $1.93M | 0.02% | Jun 30, 2026 |
| Nuveen Equity Index Fund | 330,397 | 0.51% | $1.36M | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 281,673 | 0.43% | $1.63M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 180,332 | 0.28% | $899.86K | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Benjamin J. Zeskind | PRESIDENT AND CEO, Director | 3,210,179 | 4.96% | Jun 24, 2026 |
| Andrew Gengos | Chief Financial Officer | 225,000 | 0.35% | Jul 17, 2026 |
| Brett Matthew Hall | CHIEF SCIENTIFIC OFFICER | 382,531 | 0.59% | Jun 16, 2026 |
| Leah R. Neufeld | CHIEF PEOPLE OFFICER | 29,598 | 0.05% | Mar 17, 2026 |
| Michael Bookman | CHIEF LEGAL OFFICER, SECRETARY | 4,870 | 0.01% | Feb 5, 2026 |
| Igor Matushansky | Chief Medical Officer | – | – | Feb 5, 2026 |
| Harold Eugene Brakewood | Chief Business Officer | 11,050 | 0.02% | Feb 5, 2026 |
| Mallory Morales | SVP Finance, CAO | 27,533 | 0.04% | Feb 5, 2026 |
| Grant C. Bogle | Director | – | – | Nov 9, 2026 |
| Diana Hausman | Director | 5,500 | 0.01% | Jun 11, 2026 |
| Peter Feinberg | Director | 1,161,064 | 1.79% | Jun 11, 2026 |
| Robert J. Carpenter | Director | 1,148,839 | 1.77% | Jun 11, 2026 |
| Thomas J. Schall | Director | 74,530 | 0.12% | Jun 11, 2026 |
| Laurie Keating | Director | 14,000 | 0.02% | Jun 11, 2026 |
| Ann E. Berman | Director | 67,465 | 0.10% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Benjamin J. Zeskind PRESIDENT AND CEO, Director | Jun 23, 2026 | Buy | +2,400 | $4.56 | $10.94K | 2,315,252 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Jun 15, 2026 | Buy | +6,035 | $4.15 | $25.05K | 382,531 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Mar 13, 2026 | Award | +3,628 | $4.29 | $15.56K | 29,598 |
| Harold Eugene Brakewood Chief Business Officer | Jan 16, 2026 | Buy | +5,250 | $4.76 | $24.99K | 11,050 |
| Thomas J. Schall Director | Jan 15, 2026 | Buy | +21,645 | $4.67 | $101.08K | 74,530 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Jan 15, 2026 | Buy | +2,298 | $4.57 | $10.50K | 376,496 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Jan 13, 2026 | Buy | +2,626 | $4.15 | $10.90K | 25,970 |
| Peter Feinberg Director | Jan 12, 2026 | Buy | +20,000 | $4.35 | $87.00K | 135,441 |
| Peter Feinberg Director | Oct 3, 2025 | Buy | +7,500 | $6.67 | $50.03K | 156,766 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Oct 1, 2025 | Buy | +800 | $6.38 | $5.10K | 23,344 |
| Mallory Morales Chief Accounting Officer | Oct 1, 2025 | Buy | +300 | $6.39 | $1.92K | 27,533 |
| Michael Bookman CHIEF LEGAL OFFICER, SECRETARY | Oct 1, 2025 | Buy | +1,020 | $6.83 | $6.97K | 4,870 |
| Peter Feinberg Director | Sep 30, 2025 | Buy | +7,500 | $7.03 | $52.73K | 149,266 |
| Peter Feinberg Director | Sep 29, 2025 | Buy | +5,000 | $7.18 | $35.90K | 141,766 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Sep 15, 2025 | Award | +14,880 | $1.43 | $21.28K | 374,198 |
| Mallory Morales Chief Accounting Officer | Sep 15, 2025 | Award | +14,497 | $1.43 | $20.73K | 27,233 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Sep 15, 2025 | Award | +11,815 | $1.43 | $16.90K | 22,544 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Jul 2, 2025 | Buy | +700 | $3.57 | $2.50K | 10,729 |
| Diana Hausman Director | Jul 2, 2025 | Buy | +3,000 | $3.62 | $10.86K | 3,000 |
| Diana Hausman Director | Jul 2, 2025 | Buy | +2,500 | $3.60 | $9.00K | 2,500 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Jul 2, 2025 | Buy | +7,015 | $3.53 | $24.76K | 2,312,852 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Jul 1, 2025 | Buy | +2,985 | $3.38 | $10.09K | 2,305,837 |
| Thomas J. Schall Director | Jun 27, 2025 | Buy | +9,500 | $3.66 | $34.77K | 52,885 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Jun 23, 2025 | Buy | +6,007 | $2.43 | $14.60K | 359,318 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Jun 20, 2025 | Buy | +7,415 | $2.70 | $20.02K | 353,311 |
| Harold Eugene Brakewood Chief Business Officer | Jun 20, 2025 | Buy | +1,900 | $2.53 | $4.81K | 5,800 |
| Peter Feinberg Director | Jun 18, 2025 | Buy | +25,000 | $2.53 | $63.25K | 136,766 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Jun 18, 2025 | Buy | +21,000 | $2.39 | $50.19K | 2,302,852 |
| Thomas J. Schall Director | Jun 17, 2025 | Buy | +40,485 | $2.21 | $89.47K | 43,385 |
| Mallory Morales Chief Accounting Officer | Sep 15, 2024 | Award | +4,458 | $1.62 | $7.22K | 12,736 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −100 | $3.05 | $305 | 3,294,773 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −600 | $3.03 | $1.82K | 3,294,173 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −100 | $3.07 | $307 | 3,295,173 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −300 | $3.07 | $921 | 3,294,873 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −398,600 | $2.90 | $1.16M | 2,895,273 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −10 | $3.01 | $30 | 3,294,163 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −10 | $2.98 | $30 | 3,294,153 |
| Private Healthcare Fund III LP Cormorant 10% owner | Apr 1, 2024 | Sale | −280 | $2.97 | $832 | 3,293,873 |
| Peter Feinberg Director | Mar 22, 2024 | Buy | +25,000 | $2.55 | $63.75K | 111,766 |
| Thomas J. Schall Director | Mar 22, 2024 | Buy | +2,900 | $2.55 | $7.39K | 2,900 |
| Harold Eugene Brakewood Chief Business Officer | Mar 22, 2024 | Buy | +3,900 | $2.57 | $10.02K | 3,900 |
| Mallory Morales Chief Accounting Officer | Mar 22, 2024 | Buy | +393 | $2.55 | $1.00K | 8,278 |
| Mallory Morales Chief Accounting Officer | Mar 21, 2024 | Buy | +1,107 | $2.72 | $3.01K | 7,885 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Mar 20, 2024 | Buy | +7,000 | $2.86 | $20.02K | 345,896 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Mar 20, 2024 | Buy | +3,818 | $2.88 | $11.00K | 10,029 |
| Peter Feinberg Director | Mar 19, 2024 | Buy | +25,000 | $2.56 | $64.00K | 86,766 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Mar 19, 2024 | Buy | +20,000 | $2.77 | $55.40K | 2,281,852 |
| Peter Feinberg Director | Mar 18, 2024 | Buy | +45,024 | $2.31 | $104.01K | 56,790 |
| Peter Feinberg Director | Mar 18, 2024 | Buy | +4,976 | $3.05 | $15.18K | 61,766 |
| Ann E. Berman Director | Mar 18, 2024 | Buy | +57,965 | $2.13 | $123.47K | 67,465 |
| Mallory Morales Chief Accounting Officer | Mar 15, 2024 | Award | +4,344 | $1.62 | $7.04K | 6,778 |
| Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | Mar 15, 2024 | Award | +6,211 | $1.62 | $10.06K | 338,896 |
| Leah R. Neufeld CHIEF PEOPLE OFFICER | Mar 15, 2024 | Award | +6,211 | $1.62 | $10.06K | 6,211 |
| Michael Bookman CHIEF LEGAL OFFICER, SECRETARY | Mar 15, 2024 | Award | +1,448 | $1.62 | $2.35K | 3,850 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 15, 2024 | Sale | −400,000 | $2.14 | $856.00K | 3,295,273 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 14, 2024 | Sale | −345,266 | $3.24 | $1.12M | 3,859,098 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 14, 2024 | Sale | −98,570 | $4.25 | $418.92K | 3,760,528 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 14, 2024 | Sale | −54,215 | $5.37 | $291.13K | 3,706,313 |
| Cormorant Global Healthcare Master Fund, LP 10% owner | Mar 14, 2024 | Sale | −11,040 | $5.97 | $65.91K | 3,695,273 |
| Benjamin J. Zeskind PRESIDENT AND CEO, Director, 10% owner | Dec 22, 2022 | Option exercise | +2,500 | $3.01 | $7.52K | 2,261,852 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
25.49%
15M shares short
Days to cover
19.2
At 1M shares a day
Change since last report
-10.6%
From 16M shares
Short volume, 20 days
42.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immuneering's stock actually held short. Settlement fails (shares not delivered on time) peaked at 248,059 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ann E. Berman Director | Sep 23, 2025 | 14,000 | $136.08K | Sep 23, 2025 | Open Market Purchase |
See a number that looks wrong?